NEW YORK (GenomeWeb) – Precision for Medicine said today that it has acquired Houston-based ApoCell, which specializes in the identification and analysis of biomarkers in both tissue and liquid biopsy.
Specific terms of the deal were not disclosed.
The acquisition adds ApoCell's ApoStream liquid biopsy technology and its expertise in tissue genomic profiling to Precision's existing suite of specialty laboratory and biomarker informatics services, which include cell-based assays and various immune monitoring technologies.
ApoCell co-developed the ApoStream liquid biopsy tech in conjunction with the National Cancer Institute. The platform allows for the detection, isolation, and capture of circulating tumor cells and other rare cells without the need for labels or antibodies. Applications of the technology so far include studies in prostate, lung, breast, colon, pancreatic, liver, sarcoma, and renal cancers.
For tissue analysis, ApoCell offers an integrated platform for parallel generation of both phenotypic and genomic information from the same tissue biopsy sample, including high complexity, multiplex immunofluorescence detection.